We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Srp4.0
Serrapeptase Research
Mostly mechanism / observational
24 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Serrapeptase studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1983–2026 with a typical study size of 90 participants.
Based on 24 studies · 2 meta-analyses · 14 RCTs · 576 total participants
Confidence
High confidence
What the studies found
0helped1unclear· 23 more without graded effect data
InflammationReduced swelling and inflammation · 1-2 weeks
Mostly mechanism / observational5 studies
Pain & analgesia
Mostly mechanism / observational4 studies
Therapeutic & clinical
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Women's health
Too few graded studies2 studies
Heart & blood pressure
Too few graded studies2 studies
By the numbers
Pulled from 10 studies with measurable effects
People studied
576
typical study: 90 people
Strongest designs
16
2 pooled, 14 randomised
Showed benefit
0%
0/1 studies
How long studies ran
Under a week
1
1–4 weeks
1
1–3 months
1
Populations Studied
Cardiovascular patients1
Patients with blood thrombi1
Patients undergoing impacted molar surgery1
patients with inflammatory conditions1
Steady research
7 studies in the last 5 years · Latest meta-analysis: 2021
198320042026
1Serratiopeptidase therapeutic applications and improvementsSystematic ReviewCited 1×2024
Hosseini SB et al. · Archives of microbiology (2024)
To overcome such limitations, improved versions of the enzyme were introduced using protein engineering in our previous studies.
Novel functional serratiopeptidases with shorter length and higher stability have seemingly created a hope for using this enzyme as a more effective therapeutic enzyme.
2Serratiopeptidase therapeutic and clinical applicationsSystematic ReviewCited 24×2022
In addition, the review highlights the therapeutic and clinical aspects of the serratiopeptidase enzyme to combat COVID-19-induced respiratory syndrome.
Nair SR et al. · Biomolecules (2022)
Existing serratiopeptidase treatments in combination with antibiotics are popular in the treatment of postoperative swelling.
Although an exclusive number of serratiopeptidase-producing strains have been derived, there is an urge for new recombinant strains to enhance the production of the enzyme.
This review explores the properties of serratiopeptidase, different therapeutic aspects, industrial production, and various analytical techniques used in enzyme recovery.
This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy.
Kotb E · Biotechnology progress (2014)
According to data provided by the World Health Organization (WHO) in 2000, heart diseases are responsible for 29% of the total mortality rate in the world.
Furthermore, recombinant DNA technology has succeeded in improving and decreasing the undesirable effects of the first generation of enzymes.
This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy.